TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
D.Western Therapeutics Institute ( (JP:4576) ) just unveiled an update.
D.Western Therapeutics Institute has announced a joint research agreement with Chordia Therapeutics to develop therapeutic agents for ophthalmic diseases using a compound from Chordia’s oncology pipeline. This collaboration leverages both companies’ expertise and resources, with Chordia providing research materials and D.Western conducting efficacy studies. While this partnership will not affect the current fiscal year’s earnings forecast, it is expected to expand D.Western’s ophthalmology pipeline in the medium to long term.
More about D.Western Therapeutics Institute
D.Western Therapeutics Institute is a biotech company focused on creating innovative new drugs, particularly kinase inhibitors, with a specialization in the ophthalmic field. The company is dedicated to providing effective medicines quickly and is engaged in drug discovery and regenerative medicine products to enhance patient treatment options.
Average Trading Volume: 946,168
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.21B
Find detailed analytics on 4576 stock on TipRanks’ Stock Analysis page.